Penn Medicine Advanced Lipid Management: Everything You Need to Know About Lipoprotein(a) 2026 (Videos)

Advanced Lipidology, Preventive Cardiology & Cardiovascular Risk Reduction

Overview

Penn Medicine Advanced Lipid Management: Everything You Need to Know About Lipoprotein(a) 2026 is a specialized cardiovascular education program focused exclusively on Lipoprotein(a) [Lp(a)], one of the most important inherited and underrecognized risk factors for atherosclerotic cardiovascular disease (ASCVD). This expert-led course provides a comprehensive review of Lp(a) biology, cardiovascular risk assessment, screening recommendations, clinical management strategies, and emerging therapies that are expected to transform preventive cardiology in the coming years.

Held online on February 6, 2026, this advanced lipid management symposium brings together leading experts in preventive cardiology, lipidology, and cardiovascular medicine to review current scientific evidence and practical approaches for identifying and managing patients with elevated Lp(a).

The course explores the growing role of Lp(a) in coronary artery disease, stroke, aortic valve disease, and residual cardiovascular risk while providing clinicians with the tools necessary to integrate Lp(a) testing into routine cardiovascular practice.

Course Specifications

• Course: Penn Medicine Advanced Lipid Management
• Topic: Everything You Need to Know About Lipoprotein(a)
• Date: February 6, 2026
• Format: Online Video Conference
• Level: Intermediate to Advanced
• Educational Focus: Lipidology, Preventive Cardiology & Cardiovascular Risk Assessment

Course Overview

Lipoprotein(a), commonly abbreviated Lp(a), has emerged as a major independent cardiovascular risk factor associated with:

• Coronary artery disease
• Myocardial infarction
• Ischemic stroke
• Peripheral arterial disease
• Calcific aortic valve stenosis
• Premature cardiovascular disease

Despite its clinical significance, Lp(a) remains underdiagnosed and underutilized in cardiovascular risk assessment. Growing evidence supports broader screening strategies and the incorporation of Lp(a) measurement into preventive cardiology programs.

This course provides an in-depth review of:

• Lp(a) biology and genetics
• Cardiovascular risk implications
• Patient screening strategies
• Interpretation of Lp(a) results
• Current treatment approaches
• Emerging RNA-based therapies
• Future directions in lipid management

Participants will gain practical knowledge that can be immediately applied to improve cardiovascular prevention and patient outcomes.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe the biology and genetic determinants of Lipoprotein(a).
• Understand the association between elevated Lp(a) and cardiovascular disease.
• Identify patients who should undergo Lp(a) screening.
• Incorporate Lp(a) measurements into cardiovascular risk assessment.
• Apply current management strategies for patients with elevated Lp(a).
• Evaluate residual cardiovascular risk related to Lp(a).
• Review emerging Lp(a)-lowering therapies currently in development.
• Integrate preventive cardiology principles into lipid management practice.
• Optimize risk reduction strategies for high-risk cardiovascular patients.

Major Topics Covered

Lipoprotein(a) Biology

Structure & Function

• Lipoprotein(a) composition
• Apo(a) structure
• Genetic inheritance patterns
• Metabolic pathways

Pathophysiology

• Atherogenic mechanisms
• Pro-inflammatory effects
• Pro-thrombotic properties
• Vascular injury and plaque development

Lp(a) and Atherosclerotic Cardiovascular Disease

Coronary Artery Disease

• Premature coronary disease
• Myocardial infarction risk
• Residual cardiovascular risk

Cerebrovascular Disease

• Ischemic stroke
• Carotid artery disease
• Cerebral vascular complications

Peripheral Arterial Disease

• Lower extremity vascular disease
• Systemic atherosclerosis

Risk Stratification

• Lp(a) as an independent risk factor
• Integration with traditional risk markers
• Risk prediction models

Lp(a) and Aortic Valve Disease

Calcific Aortic Valve Stenosis

• Mechanisms of valve calcification
• Role of Lp(a) in disease progression

Structural Heart Implications

• Early disease detection
• Clinical monitoring strategies

Future Therapeutic Opportunities

• Disease-modifying approaches
• Emerging intervention targets

Screening & Patient Selection

Who Should Be Tested?

Current recommendations for:

• Patients with premature ASCVD
• Family history of early cardiovascular disease
• Familial hypercholesterolemia
• Recurrent cardiovascular events
• Unexplained residual risk

Population Screening Strategies

• One-time lifetime screening
• High-risk population assessment
• Family cascade screening

Interpretation of Lp(a) Results

Laboratory Assessment

• Measurement techniques
• Standardization challenges
• Units and reporting

Clinical Application

• Risk categorization
• Integration into preventive care
• Shared decision-making

Current Management Strategies

Lifestyle Intervention

• Diet and nutrition
• Exercise programs
• Smoking cessation
• Weight management

Aggressive Risk Factor Modification

• LDL cholesterol reduction
• Blood pressure control
• Diabetes management
• Comprehensive ASCVD prevention

Pharmacologic Management

• Statin therapy
• Ezetimibe
• PCSK9 inhibitors
• Secondary prevention strategies

Emerging Lp(a)-Lowering Therapies

RNA-Based Therapeutics

• Antisense oligonucleotides
• Small interfering RNA (siRNA)

Novel Investigational Agents

• Targeted Lp(a) reduction therapies
• Ongoing clinical trials

Future Clinical Practice

• Expected therapeutic approvals
• Potential impact on cardiovascular prevention
• Personalized lipid management

Preventive Cardiology Applications

Advanced Cardiovascular Prevention

• Personalized risk assessment
• Precision lipid management
• Long-term cardiovascular risk reduction

High-Risk Patient Management

• Secondary prevention
• Family screening programs
• Integrated prevention strategies

Educational Features

✔ Comprehensive review of Lipoprotein(a)

✔ Advanced lipidology education

✔ Preventive cardiology updates

✔ Cardiovascular risk assessment strategies

✔ Aortic valve disease implications

✔ Emerging RNA-based therapies review

✔ Evidence-based screening recommendations

✔ Clinical management algorithms

✔ Expert faculty presentations

✔ Practical implementation guidance

Who Should Attend?

This course is ideal for:

• Cardiologists
• Lipidologists
• Preventive Cardiologists
• Internal Medicine Physicians
• Endocrinologists
• Family Medicine Physicians
• Vascular Medicine Specialists
• Cardiology Fellows
• Internal Medicine Residents
• Advanced Practice Providers
• Nurse Practitioners
• Physician Assistants

Why This Course Stands Out

✔ Dedicated entirely to Lipoprotein(a) education

✔ Focuses on one of the fastest-growing areas in preventive cardiology

✔ Reviews the latest screening recommendations

✔ Covers emerging therapies likely to change future practice

✔ Integrates lipidology with cardiovascular prevention

✔ Explains practical risk assessment strategies

✔ Strong evidence-based approach

✔ Useful for both specialists and primary care clinicians

✔ Reviews Lp(a)-associated aortic valve disease

✔ Helps clinicians prepare for future therapeutic advances

Product Details

Course: Penn Medicine Advanced Lipid Management: Everything You Need to Know About Lipoprotein(a)

Date: February 6, 2026

Format: Online Video Conference

Level: Intermediate to Advanced

Educational Focus: Lipoprotein(a), Lipidology, Preventive Cardiology & Cardiovascular Risk Reduction

4. Topics

1. Case Presentation & Q&A

2. Current Treatment Strategies for Elevated Lp(a)

3. Keynote Lecture- The Initial Journey to Develop a Therapy

4. Lp(a) and Risk for Coronary Disease and Aortic Stenosis

5. Lp(a) and Risk for Peripheral Vascular Disease

6. Lp(a) and Risk for Stroke

7. Lp(a) Biology and Role in Atherosclerosis

8. Lp(a) in Females and Effect of Hormones

9. Novel Lp(a)-Lowering Therapies in Development

10. Welcome & Introductions

11. Where Does Lp(a) fit in Current Guidelines